Successful combination treatment of metastatic ductal carcinoma of the pancreas tail pT4N0M1(per). Clinical case
https://doi.org/10.17650/2782-3202-2022-2-3-16-20
Abstract
Pancreatic tail cancer has a poor prognosis and may be unresectable at the time of diagnosis, since it is asymptomatic and often has invasion into adjacent organs, and also has a high metastatic potential, where the target organs are the liver, lungs, bones, as well as the parietal and visceral peritoneum, adrenal glands. Radical resection of the pancreas in such cases is impractical. The gold standard of treatment is systemic chemotherapy. We describe the successful resection of locally advanced pancreatic tail cancer with metastases along the peritoneum of the large omentum after 14 courses of chemotherapy according to the mFOLFIRINOX (oxaliplatin 85 mg/m2 intravenously for 120 min, irinotecan 150 mg/m2 intravenously for 90 min, leucovorin 400 mg/m2 intravenously for 120 min, 5-fluorouracil 2400 mg/m2 intravenous infusion for 46 hours, cycle 14 days).
About the Authors
E. V. Glukhov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
Evgeny V. Glukhov
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
M. M. Davydov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
A. M. Ivanov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
A. A. Filatov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
M. S. Shogenov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
E. V. Dementieva
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
References
1. GLOBOCAN: cancer incidence and mortality worldwide in 2020. Available at: http://gco.iarc.fr/
2. Hassan M.M., Bondy M.L., Wolff R.A. et al. Risk factors for pancreatic cancer: case-control study. Am J Gastroenterol 2007;102(12):2696– 707. DOI: 10.1111/j.1572-0241.2007.01510.x
3. Ohata K., Uenishi T., Miyazaki T. et al. [A resected case of the pancreatic tail cancer with obstruction of the large intestine (In Japanese)]. Nihon Gekakei Rengo Gakkaishi 2014;39(4):761–6. DOI: 10.4030/jjcs.39.761
4. Solcie E., Capella C., Kloppel G. Tumors of the pancreas. In: Atlas of tumor pathology. 3rd series, fasc. 20. Armed Forces Institute of Pathology, 1995. P. 85–86.
5. Antoniou E., Margonis G.A., Sasaki K. et al. Is resection of pancreatic adenocarcinoma with synchronous hepatic metastasis justified? A review of current literature. ANZ J Surg 2016;86(12):973–7. DOI: 10.1111/ans.13738
6. Tempero M.A., Malafa M.P., Behrman S.W. et al. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw 2014;12(8):1083–93. DOI: 10.6004/jnccn.2014.0106
7. Disibio G., French S.W. Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med 2008;132(6):931–9. DOI: 10.5858/2008-132-931-MPOCRF
8. Embuscado E.E., Laheru D., Ricci F. et al. Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther 2005;4(5):548–54. DOI: 10.4161/cbt.4.5.1663
9. Kandel P., Wallace M.B., Stauffer J. et al. Survival of patients with oligo-metastatic pancreatic ductal adenocarcinoma treated with combined modality treatment including surgical resection: a pilot study. J Pancreat Cancer 2018;4(1):88–94. DOI: 10.1089/pancan.2018.0011
10. Hackert T., Niesen W., Hinz U. et al. Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol 2017;43(2):358–63. DOI: 10.1016/j.ejso.2016.10.023
11. Takada T., Yasuda H., Amano H. et al. Simultaneous hepatic resection with pancreato-duodenectomy for metastatic pancreatic head carcinoma: does it improve survival? Hepatogastroenterology 1997;44(14):567–73.
12. Dünschede F., Will L., von Langsdorf C. et al. Treatment of metachronous and simultaneous liver metastases of pancreatic cancer. Eur Surg Res 2010;44(3–4):209–13. DOI: 10.1159/000313532
13. Gleisner A.L., Assumpcao L., Cameron J.L. et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer 2007;110(11):2484–92. DOI: 10.1002/cncr.23074
14. Seelig S.K., Burkert B., Chromik A.M. et al. Pancreatic resections for advanced M1-pancreatic carcinoma: the value of synchronous metastasectomy. HPB Surg 2010;2010:579672. DOI: 10.1155/2010/579672
15. Singh A., Singh T., Chaudhary A. Synchronous resection of solitary liver metastases with pancreaticoduodenectomy. JOP 2010;11(5):434–8.
Review
For citations:
Glukhov E.V., Davydov M.M., Ivanov A.M., Filatov A.A., Shogenov M.S., Dementieva E.V. Successful combination treatment of metastatic ductal carcinoma of the pancreas tail pT4N0M1(per). Clinical case. MD-Onco. 2022;2(3):16-20. (In Russ.) https://doi.org/10.17650/2782-3202-2022-2-3-16-20
Views:
166
Email this article 